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The Northwick Park Heart Study found that elevation of 
factor VII in middle-aged subjects was an independent risk 
factor for subsequent ischemic heart disease. The present 
study was designed to determine whether factor VII eleva- 
tion is present at a younger age and whether zymogen or 
activated factor VII is responsible for this elevation. A 
group of 20 asymptomatic first degree relatives (mean age 
34.9 years) of patients with premature iscbemic heart 
disease were compared with 15 age-matched normal sub- 
jects at low risk of ischemic heart disease and 15 older 
subjects with established ischemic heart disease (mean age 
49.7 years). Factor VII procoagulant, coupled amidolytic 
The Northwick Park Heart Study. a prospective epidemio- 
logic study of ischemic heart disease (1,2), has shown that 
factor VII procoagulant level was an independent predictive 
risk factor for ischemic cardiac events in middle-aged men 
(mean age 52 years), especially those events within 5 years 
of entry into the study. Factor VIII and fibrinogen levels 
were also positively correlated with ischemic heart disease. 
Meade et al. (2) concluded that increases in procoagulant 
proteins are partially responsible for the development of 
ischemic heart disease. 
Dalaker et al. (3) reported an elevated level of factor VII 
procoagulant activity in men at high risk for cardiovascular 
disease (mean age 42 years). This increase in factor VII 
procoagulant activity was at least partly attributable to a 
fraction of plasma factor VII that was sensitive to phospho- 
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and antigenic assays, as well as fasting serum triglyceride 
and cholesterol assays, were performed on all three groups. 
Factor VII antigen and coagulant activity was signifi- 
cantly elevated in first degree relatives, as was factor VII 
antigen in the patients with ischemic heart disease. The 
increased factor VII level in these subjects was caused by 
elevated factor VII zymogen, not activated factor VII. The 
results of this study, combined with those of previous 
studies, suggest that factor VII may be a useful additional 
marker of the risk for ischemic heart disease and merits 
further investigation. 
(J Am Co11 Cardiol1989;14:941-6) 
lipase C. and showed a significant positive correlation with 
plasma triglycerides (3). In addition, these investigators 
reported the presence of this phospholipase C-sensitive 
factor VII in male survivors of acute myocardial infarction 
(4). The Prospective Cardiovascular Munster Study (5,6) 
also found a positive correlation of factor VII procoagulant 
levels and body weight index (5) and plasma triglycerides (6). 
These studies (I-61, however, did not indicate whether there 
was an elevation in factor VII levels in younger persons at 
risk for ischemic heart disease. It was also unclear whether 
zymogen factor VII or activated factor VII was responsible 
for this elevation. 
Seligsohn et al. (7) developed a coupled amidolytic assay, 
using a factor VII clotting assay that was extremely sensitive 
to activated factor VII, and a factor VII amidolytic assay 
that was insensitive to activated factor VII (7-9). The ratio of 
the factor VII clotting assay to the amidolytic assay was a 
measure of the presence of activated factor VII (7). A 
standard one stage factor VII clotting assay used in our 
laboratory (8,9) was also somewhat sensitive to activated 
factor VII. Recently, a factor VII enzyme immunoassay has 
become available to measure factor VII antigen (Diagnostica 
Stage). Tirindelli et al. (IO) reported good correlation (r = 
0.86) between factor VII antigen levels, as measured by this 
enzyme immunoassay. and factor VII procoagulant levels, 
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as measured by their one stage procoagulant assay, both in 
normal subjects and in patients with congenital factor VII 
deficiency. The factor VII enzyme immunoassay had low 
values of intra- and interassay coefficients of variation (4% 
and 5%, respectively). In addition, the authors (IO) confirmed 
that this enzyme immunoassay was specific for factor VII. 
We previously reported (8) an elevated level of factor VII 
amidolytic and procoagulant activity in middle-aged men and 
women (mean age 52 years) at high risk of ischemic heart 
disease. This increased level of total factor VII was not 
associated with an increase in activated factor VII and, 
therefore, presumably reflected an increase in zymogen 
factor VII. The factor VII levels in these subjects correlated 
with fasting serum triglyceride concentrations. However, 
factor VII antigen levels were not measured. 
We hypothesized that factor VII levels in younger sub- 
jects at high risk of ischemic heart disease should be elevated 
if factor VII elevation was related to the cause or progres- 
sion of ischemic heart disease, or both, rather than merely a 
result of it. If this was the case, factor VII antigen levels 
should also be elevated in both middle-aged and younger 
subjects at high risk for ischemic heart disease. To test these 
hypotheses, a prospective study was designed to compare 
factor VII activity and antigen and lipid levels in three 
groups: middle-aged patients with established ischemic heart 
disease, asymptomatic young first degree relatives at high 
risk of premature ischemic heart disease and low risk normal 
subjects. 
Methods 
Study patients. The protocol for obtaining blood samples 
was approved by the Committee on Research Involving 
Human Subjects at the State University of New York at 
Stony Brook. Written informed consent was obtained from 
all study participants. Both men and women, 23 to 66 years 
old, were recruited. Data were collected on each subject, 
regarding age, gender, height, weight, medication usage and 
risk factors for ischemic heart disease. 
The ischemic heart disease group consisted of 1.5 patients 
with proved ischemic heart disease. Included in this group 
were six men, 45 to 66 years old, admitted to University 
Hospital for elective coronary arteriography and nine pa- 
tients (eight men and one woman, 32 to 66 years old) enrolled 
in the outpatient clinics at University Hospital. All subjects 
were ambulatory and in stable clinical condition. The mean 
age of the entire study group was 49.7 years. All subjects 
received some form of medication for treatment of cardio- 
vascular disease, hypertension, or diabetes mellitus. Arte- 
riographic diagnosis of coronary artery disease was made by 
the cardiologist performing the procedure. Outpatients had a 
medical history of myocardial infarction, previous positive 
diagnosis of coronary artery disease by arteriography or a 
previous positive stress test. 
The 20 young asymptomatic$rst degree relatives at risk 
of premature ischemic heart disease were enrolled in the 
preventive cardiology clinic at University Hospital. The 
group comprised 13 men and 7 women, representing 19 
different families. Their ages ranged from 25 to 49 years 
(mean 34.9). All subjects had a first degree relative (that is, 
parent or sibling) who had had an ischemic cardiac event 
prematurely (defined as ~60 years old for women, ~50 years 
old for men), as determined by a carefully performed history 
taking. Some subjects also had a family history of hyperten- 
sion, diabetes mellitus or lipid abnormalities (16 subjects); a 
social history of high alcohol consumption or smoking, or 
both (four subjects are current smokers, seven subjects had 
a history of smoking) or a medical history of hypertension 
(four subjects), obesity (four subjects) or diabetes mellitus 
(one subject). Two subjects were taking a beta-adrenergic 
blocking agent, two antibiotics and two nonsteroidal antiin- 
flammatory drugs. 
Fifteen normal healthy subjects (10 men, 5 women) who 
approximated the jirst-degree relative group by age and 
gender also participated in this study. Their ages ranged 
from 23 to 42 years (mean 32.4) and none were smokers. All 
subjects were at low risk for ischemic heart disease, having 
none of the aforementioned known risk factors for ischemic 
heart disease. Only one subject was on medication (a ceph- 
alosporin antibiotic). 
Blood samples. Citrated blood samples were collected by 
a double syringe technique, as previously reported (9). The 
first syringe was emptied into a sterile silicon-coated tube 
(Becton Dickinson Vacutainer Systems) for serum choles- 
terol and triglyceride determinations. The contents of the 
second syringe were added immediately to 0.1 vol of 3.8% 
sodium citrate. Plasma was separated by centrifugation at 
3,000 x g for 20 min at 4°C within 1 h of blood collection and 
stored at -70°C until assay (51 month). Both patient and 
normal plasma samples were stored for comparable times 
before being assayed. All samples were kept at room tem- 
perature before centrifugation to avoid cold activation (11). 
All subjects in this study had fasted overnight before veni- 
puncture. Samples from patients undergoing coronary arte- 
riography were obtained between 8 and 10 AM on the day the 
coronary arteriography was to be performed. Samples from 
all other subjects were also obtained between 8 and 10 AM. 
Standard factor VII clotting assay. The standard one- 
stage factor VII clotting assay was performed on a Fibrome- 
ter, as previously described (8,9), with human factor VII- 
deficient plasma (George King Biomedical) and a rabbit 
brain thromboplastin-calcium mixture (Simplastin, Organon 
Teknika, Durham, North Carolina). 
Factor VII enzyme immunoassay. A factor VII enzyme 
immunoassay (Diagnostica Stago, Asnieres-sur-seine, 
France) was purchased from American Bioproducts Com- 
pany. Pooled normal plasma was diluted in phosphate- 
buffered saline/bovine serum albumin/Tween-20 supplied by 
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Diagnostica Stago and assayed in triplicate at l/20, l/40, l/80 
and 11100 dilutions. Test samples were also diluted in the 
same buffer and assayed in duplicate at 1150 and l/80 
dilutions. Pooled normal plasma samples were added to the 
first, the middle and the last wells of the microplate. Test 
samples were added systematically to the microwells so that 
no duplicates of any given sample would be read next to each 
other. Because the optical density of the 1120 dilution was 
often >1.9, beyond the range of the microplate reader, the 
anti-factor VII antigen-peroxidase conjugate was used at half 
the recommended concentration, on the advice of American 
Bioproducts Company. All other procedures were followed 
according to the manufacturer’s directions. Washing solu- 
tion, anti-factor VII antigen-peroxidase conjugate and or- 
thophenylenediamine substrate were supplied by Diagnos- 
tica Stago. Hydrogen peroxide (30%; certified American 
Chemical Society [ACS] grade) was from Fisher. The optical 
density at 492 nm was determined by a microplate reader 
(Dynatech). The interassay coefficient of variation of this 
assay was 4.2%, based on the performance of seven deter- 
minations of a single normal donor’s plasma over an 8 month 
period. 
Factor VII activity state. The factor VII activity state of 
the subjects’ plasma samples was determined by the ratio of 
the Seligsohn factor VII clotting assay to the factor VII 
amidolytic assay (7). with minor modifications as previously 
described (8,9). 
Cholesterol and triglycerides. Serum cholesterol and tri- 
glyceride levels were assayed by DART reagent methods 
(Coulter Diagnostics) on a DACOS analyzer (Coulter) ac- 
cording to the manufacturer’s directions. Results were cal- 
culated in milligrams per deciliter. High density lipoprotein 
fractions were prepared by phosphotungstic acid-magnesium 
precipitation (12) and analyzed on a KDA analyzer (Amer- 
ican Monitor). 
Reference pooled normal plasma was prepared in our 
laboratory from healthy male and female volunteers (mean 
age 32 years) and was arbitrarily assumed to have 100% 
factor VII activity. A single normal donor’s plasma was 
assayed with each set of factor VII assays to serve as a daily 
internal control. 
Statistical analysis. Results of coagulation and enzyme 
immunoassays were analyzed on an IBM personal computer 
by log transformation of the data in the Parlin program for 
parallel line analysis of bioassays (13), which calculates 
probability (p) values for linearity and parallelism of the lines 
for standard plasma and test plasma. If the p values for either 
linearity or parallelism were ~0.02, the assay results were 
considered invalid and the assay repeated. 
To determine significant differences in factor VII levels 
between the low risk normal subject group and either the 
first degree relative or ischemic heart disease group, Stu- 
dent’s t test for independent samples was used (14). A p 
value ~0.05 in a one-tailed test was considered significant 
because the hypothesis to be tested concerned a unidirec- 
tional difference in factor VII (an increase). Significant 
differences in serum lipid levels between low risk normal 
subjects and either the first degree relative or ischemic heart 
disease group were determined by two-tailed Wilcoxon rank 
sum test (15). Correlation of factor VII assays and fasting 
serum triglycerides was determined by Spearman’s rho (p) 
statistic (16). 
Activated factor VII. The following experiment was per- 
formed to determine whether the factor VII enzyme immu- 
noassay was sensitive to activated factor VII. Freshly drawn 
titrated plasma from a normal woman on oral contraceptive 
therapy was allowed to cold-activate in a glass test tube at 
4°C for 24 h. Factor VII activity was measured before and 
after cold activation by the standard procoagulant assay, the 
Seligsohn procoagulant assay and the factor VII enzyme 
immunoassay. Prothrombin times were also measured on a 
Fibrometer. using Simplastin reagent. 
Results 
Factor VII assays. The standard one stage factor VII 
procoagulant assay and the factor VII enzyme immunoassay 
of antigen levels were performed on all members of the low 
risk normal, high risk first degree relative and ischemic heart 
disease patient groups (Table 1). The first degree relative 
group showed significant elevations in factor VII activity and 
antigen levels compared with the low risk normal group. The 
ischemic heart disease group also showed a significant 
elevation in factor VII antigen levels compared with the low 
risk normal group. Factor VII procoagulant activity also 
correlated significantly with factor VII antigen levels in the 
first degree relative, ischemic heart disease and low risk 
normal groups (p < 0.001, <O.OOl and CO.01 and r = 0.77, 
0.87 and 0.65 respectively) (Fig. 1 and 2). 
The blood samples from first 13 to 14 subjects in each 
group were assayed by the Seligsohn-coupled amidolytic 
assay to detect activated factor VII (Table 2); factor VII 
antigen results are also included in Table 2 for comparison. In 
the normal group, agreement among the three methods was 
excellent. The mean value for the Seligsohn factor VII 
clotting assay was less than or equal to that for the amidolytic 
and antigen assay in both the ischemic heart disease group 
and the first degree relative group. The ratio of the factor VII 
clotting assay to the amidolytic assay-an indicator of acti- 
vated factor VII if elevated (7kwas essentially identical in 
the three groups. Therefore, neither the first degree relative 
nor the ischemic heart disease group had an increase in 
activated factor VII compared with that in the normal group. 
Factor VII amidolytic and antigen levels were significantly 
correlated in first degree relative (r = 0.92; p < 0.001) and 
ischemic heart disease groups (r = 0.84; p < 0.001). 
Cholesterol and triglycerides (Table 1, Fig. 3 and 4). The 
first degree relative group showed a significant elevation of 
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Table 1. Factor VII Assay Results and Fasting Lipid Values in the Three Subject Groups 
FVIlc-A FVII-EIA 
(mean %) (mean %) 
Cholesterol 
(mg/dl) 
Triglycerides 
(mg/dl) 
Low risk 
normal subjects (n = IS) 
(mean age 32.4 yr) 
High risk 
first-degree relatives of patients 
with IHD (n = 20) (mean age 
34.9 yr) 
Patients with ischemic heart disease 
(n = 15) (mean age 49.7 yr) 
103 + 19 
(64 to 138) 
116 + 24* 
(72 to 164) 
110 + 30 
(57 to 167) 
91 + 24 
(63 to 161) 
125 + 36t 
(55 to 210) 
118 + 32* 
(46 to 178) 
Median 175 
(145 to 232) 
Median 215$ 
(153 to 399) 
Median 2528 
(197 to 337) 
Median 40 
(18 to 258) 
Median 84t 
(28 to 399) 
Median 213$ 
(101 to 153) 
*p < 0.05 compared with low risk normal subjects; tp < 0.01 compared with low risk normal subjects; $p < 0.02 compared with low risk normal subjects; 
$p < 0.002 compared with low risk normal subjects. A standard one stage factor VII procoagulant assay (FVllc-A) and a factor VII antigen assay (FVII-EIA) 
were performed. Error values indicate t 1 SD (a, - 1). Figures in parentheses indicate range of value. IHD = ischemic heart disease. 
serum triglycerides and cholesterol compared with values in 
the low risk normal group. The ischemic heart disease group 
also had significantly elevated triglyceride and cholesterol 
levels compared with levels in the low risk normal group. 
There was no significant difference in triglyceride or choles- 
terol levels in the first degree relative group compared with 
those in the ischemic heart disease group. When compared 
with population studies of average weight for height (17), the 
low risk normal subjects had an average weight 5% higher 
than expected, versus an average weight for height 14% 
higher than expected in the first degree relative group and 
26% higher than expected in the ischemic heart disease 
group. Median high density lipoprotein levels were 53 mgldl 
and 44 mgldl for the first degree relative and ischemic heart 
disease groups, respectively (p = NS). There was no signif- 
icant correlation between either the standard factor VII 
procoagulant assay or the factor VII enzyme immunoassay 
and fasting serum triglyceride levels in any of the three 
groups. 
Effects of activated factor VII. Table 3 summarizes the 
effects of cold-promoted activation of factor VII on pro- 
thrombin time, Seligsohn factor VII clotting assay, standard 
factor VII clotting assay and factor VII enzyme immunoas- 
Figure 1. Correlation coefficients (r) and linear regression of stan- 
dard factor VII procoagulant assay (FVII-C) versus factor VII 
antigen assay (FVII-AG) in 20 young asymptomatic first degree 
relatives of patients with ischemic heart disease. 
I 
0 I I 50 100 150 00 
FV I I -AG CO,,) 
say. The subject taking oral contraceptives had a normal 
prothrombin time and normal levels of factor VII by all three 
assays before cold activation. After cold-promoted activa- 
tion of factor VII, the subject had a shortened prothrombin 
time, a 25 and 5-fold increase in factor VII activity by the 
Seligsohn and standard factor VII clotting assays, respec- 
tively, and no change in antigen levels. Thus, the three 
clotting assays were all sensitive, in varying degrees, to 
activated factor VII, but the factor VII antigen assay was 
unaffected. 
Discussion 
Factor VII elevation. This study demonstrates that both 
factor VII activity and antigen levels are elevated in young 
first degree relatives of patients with ischemic heart disease 
and in patients with established ischemic heart disease. We 
conclude that this elevation is primarily due to an elevation 
in factor VII zymogen, rather than to activated factor VII, 
for two reasons. First, factor VII activity did not exceed 
factor VII antigen in either patient group, whereas we 
showed that activated factor VII increases procoagulant 
assays, but not the antigen assay. Second, the coupled 
Figure 2. Correlation coefficient (r) and linear regression of stan- 
dard factor VII procoagulant assay (FVII-C) versus factor VII 
antigen assay (FVII-AG) in 15 patients with ischemic heart disease. 
200 
- 150 
o* 
FV I I -AG (Wo, 
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Table 2. Factor VII Assays Indicating Activity State in the Three Subject Groups 
Low risk normal subjects (n = 13) 
(mean age 32 yr) 
High risk first degree relatives 
of patients with IHD (n = 13) 
(mean age 34.4 yr) 
Patients with ischemic heart disease 
(n = 14) (mean age 49.4 yr) 
FVllc-B FVlIam FVllc-BiFVllam FVII-EIA 
(mean 5%) (mean 76) (mean) (mean 7%) 
97 + 33 100 ? 18 0.99 94+ 16 
113 ? 44 110 + 29 I.02 125 5 40 
98 ? 28 104 2 27 0.95 119 t 33 
The ratio of the FVllc-BIFVIlam assay is an indication of the factor VII activity state. The FVII enzyme 
immunoassay (FVII-EIA) of factor VII antigen is included for comparison. Error values indicate ? I SD (g” - I). 
FVIIc-B = Seligsohn’s factor VII procoagulant assay. FVlIam = factor VII amidolytic assay: other abbreviations as 
in Table I. 
amidolytic assay for activated factor VII showed no increase 
in activated factor VII in the study groups compared with 
that in the normal group. 
Hyperlipidemia. First degree relatives of patients with 
premature ischemic heart disease and patients with estab- 
lished ischemic heart disease both had significantly elevated 
serum levels of total cholesterol and triglycerides compared 
with values in the normal low risk subjects, although most of 
the first degree relatives had values within the normal range 
for our laboratory. Obesity may partly account for the 
elevated lipid levels in these groups (18), and beta-blocker 
medication may be involved in the triglyceride elevations in 
some patients with ischemic heart disease. 
Figure 3. Fasting serum cholesterol levels in 15 normal low risk 
subjects (NL), 20 first degree relatives of patients with premature 
ischemic heart disease (FDR) and 15 patients with established 
ischemic heart disease (IHD). Horizontal bars indicate the median 
value for each group. 
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Factor VII as a risk factor. Previous studies (1,3,6,9) of 
middle-aged subjects reported a positive correlation between 
factor VII activity levels and serum triglycerides. Factor VII 
antigen has also been found to be associated with triglycer- 
ide-rich lipoproteins, especially chylomicra and very low 
density lipoprotein fractions (19). Our failure to detect a 
significant correlation between factor VII levels and triglyc- 
erides in this study may reflect an insufficient power of the 
statistical tests because of the small sample size or a true 
lack of correlation. We suspect the former explanation is the 
case for the ischemic heart disease group. Indeed, when we 
analyze the cumulative data of 30 subjects with proved 
ischemic heart disease from this and our previous study (9), 
we find a significant correlation between triglyceride levels 
and factor VII clotting activity (p = 0.342; p < 0.05). In a 
recent reanalysis of its data, the Framingham Study (18) 
concluded that triglyceride elevation is an independent risk 
factor for coronary heart disease in both men and women, a 
Figure 4. Fasting serum triglyceride levels in 15 normal low risk 
subjects (NL), 20 first degree relatives of patients with premature 
ischemic heart disease (FDR) and 15 patients with established 
ischemic heart disease (IHD). Horizontal bars indicate the median 
value for each group. 
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Table 3. Effects of Cold-Promoted Activation of Factor VII 
PNP 
OC subject 
PT FVIIc-B FVIlc-A FVII-EIA 
(s) (%I @I @I 
12.3 100 100 100 
3. Dalaker K, Hjermann 1, Prydz H. A novel form of factor VII in plasma 
from men at risk for cardiovascular disease. Br J Haematol 1985; 
61:315-22. 
4. Dalaker K, Smith P, Arnesen H, Prydz H. Factor VII-phospholipid 
complex in male survivors of acute myocardial infarction. Acta Med 
Stand 1987:222: I 11-6. 
Fresh plasma 12.3 100 94 120 
24 h cold activation 9.8 2520 490 121 
OC subject = normal woman taking oral contraceptives; PNP = pooled 
normal plasma from normal healthy volunteers; PT = prothrombin time: other 
abbreviations as in Tables I and 2. See text for details. 
5. Balleisen L, Bailey J, Epping P-H, Schulte H, van de Loo J. Epidemio- 
logical study on factor VII, factor VIII and fibrinogen in an industrial 
population. I. Baseline data on the relation to age, gender, body-weight, 
smoking, alcohol, pill-using, and menopause. Thromb Haemost 1985; 
54:475-9. 
finding in agreement with other large studies (20). Thus, 
factor VII elevation might simply be a marker of the lipo- 
protein abnormality reflected by total triglyceride levels and 
not an independent risk factor. However, the Northwick 
Park Heart Study (1,2) did find that factor VII level was an 
independent predictive risk factor by multivariate analysis. 
Furthermore, there is ample precedent for two risk factors 
being significantly correlated and yet independent risk fac- 
tors by multivariate analysis (for example, smoking and 
fibrinogen levels) (21). Bajaj et al. (22) reported that very low 
density lipoproteins, which are rich in triglycerides, can 
enhance the rate of conversion of prothrombin to thrombin 
in the presence of factor Xa and calcium ions. Thus, an 
increase in factor VII and very low density lipoproteins may 
promote a hypercoagulable state that contributes to the 
thrombotic component of ischemic heart disease. 
6. Balleisen L, Assmann G, Bailey J, Epping P-H, Schulte H, van de Loo J. 
Epidemiological study on factor VII, factor VIII and fibrinogen in an 
industrial population. II. Baseline data on the relation to blood pressure, 
blood glucose, uric acid, and lipid fractions. Thromb Haemost 1985; 
54:721-3. 
7. Seligsohn U, Q)sterud B, Rapaport SI. Coupled amidolytic assay for factor 
VII: its use with a clotting assay to determine the activity state of factor 
VII. Blood 1978;52:978-88. 
8. Miller BC, Hultin MB, Jesty J. Altered factor VII activity in hemophilia. 
Blood 1985;65:845-9. 
9. Hoffman C, Shah A, Sodums M, Hultin MB. Factor VII activity state in 
coronary artery disease. J Lab Clin Med 1988;l ll:475-81. 
10. Tirindelli MC, Mariani G, Mazzucconi MC, et al. Evaluation of factor VII 
antigen in factor VII congenital deficiencies with a new ELISA assay. Am 
J Hematol 1987:26:313-21. 
Conclusions. Our data support the usefulness of the fac- 
tor VII antigen assay for studying the relation of factor VII 
to ischemic heart disease. The antigen assay has several 
advantages over a biologic activity assay for use in large 
scale screening studies, particularly with regard to speed and 
precision. The elevation of factor VII in subjects at risk of 
ischemic heart disease is primarily related to zymogen factor 
VII. This study lends further support to previous studies 
suggesting that an elevated factor VII level is a risk factor for 
ischemic heart disease. We believe that further biochemical 
and epidemiologic studies are needed to clarify the relation 
of factor VII to ischemic heart disease. 
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